Breaking News

Thermo Fisher Buys Patheon for $7.2B

Provides entry into the high-growth CDMO market

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Thermo Fisher Scientific, the world’s leading maker of scientific instruments, said it is acquiring Dutch contract development and manufacturing organization (CDMO) Patheon NV for $7.2 billion, expanding its capabilities to become a one-stop shop for drug development and manufacturing services. Patheon provides services to help biopharmaceutical companies of all sizes with their development and manufacturing needs. It is a leader in the high-growth, $40 billion CDMO market, which is fueled by...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters